Pure delta-9-tetrahydrocannabinol and its combination with cannabidiol in treatment-resistant Tourette syndrome: A case report.

Rate this post

Pure delta-9-tetrahydrocannabinol and its combination with cannabidiol in treatment-resistant Tourette syndrome: A case report.

Int J Psychiatry Med. 2018 Jul 30;:91217418791455

Authors: Pichler EM, Kawohl W, Seifritz E, Roser P

Abstract
Objectives Anecdotal reports and preliminary studies suggest a therapeutic potential of cannabis in Tourette syndrome. We report the case of a female patient suffering from treatment-resistant Tourette syndrome. Methods Guideline-directed antipsychotic treatment with risperidone and aripiprazole as well as pure delta-9-tetrahydrocannabinol had no significant effect on Tourette syndrome symptomatology. Results Following administration of a daily dosage of 10 mg delta-9-tetrahydrocannabinol combined with 20 mg cannabidiol (CBD), the patient showed a rapid and highly significant improvement in the Yale Global Tic Severity Scale. Conclusions It can be speculated whether the beneficial effects may rely on the pharmacological properties of cannabidiol.

PMID: 30058466 [PubMed – as supplied by publisher]


Source: Estudios sobre Cannabidiol (CBD)

Deja un comentario

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

*

Translate »